Evidence map›Paper›PMID 32210968›Full record

ArticleFrontiers in immunology2020

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.

Mehdi R Pirozyan, Helen M McGuire, Abdullah Al Emran, Hsin-Yi Tseng, Jessamy C Tiffen, Jenny H Lee, Matteo S Carlino, Alexander M Menzies, Georgina V Long, Richard A Scolyer and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mehdi R PirozyanMelanoma Immunology and Oncology, Centenary Institute, Sydney, NSW, Australia.
Helen M McGuireRamaciotti Facility for Human Systems Biology, The University of Sydney, Sydney, NSW, Australia.
Abdullah Al EmranMelanoma Immunology and Oncology, Centenary Institute, Sydney, NSW, Australia.
Hsin-Yi TsengMelanoma Immunology and Oncology, Centenary Institute, Sydney, NSW, Australia.
Jessamy C TiffenMelanoma Immunology and Oncology, Centenary Institute, Sydney, NSW, Australia.
Jenny H LeeMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Matteo S CarlinoMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Alexander M MenziesMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Georgina V LongMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Barbara Fazekas de St GrothRamaciotti Facility for Human Systems Biology, The University of Sydney, Sydney, NSW, Australia.
Peter HerseyMelanoma Immunology and Oncology, Centenary Institute, Sydney, NSW, Australia.
The University of Sydney · AUMelanoma Institute Australia · AUCentenary Institute · AUNew South Wales Department of Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of changes in T cells, referred to as T cell exhaustion, has been suggested as a cause of primary or acquired resistance to immunotherapy by immune checkpoint blockade (ICB). A limited number of studies, largely performed on tumor infiltrating lymphocytes (TILs), has provided evidence in support of this hypothesis, but whether similar changes occur in circulating blood lymphocytes has received little attention. In the present study, a comprehensive analysis of peripheral blood leukocytes from 42 patients taken over the course of treatment with anti-PD-1 was undertaken. The patients included those grouped as responders (who did not progress), primary non-responders (primary resistance) and those with acquired resistance (who initially responded then subsequently progressed). Analysis included surface markers of exhaustion, production of cytokines following

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, PharmacologicalCD4-Positive T-LymphocytesCells, CulturedFemaleHumansImmune Checkpoint InhibitorsImmune ToleranceImmunity, InnateImmunotherapyInterferon-gammaKiller Cells, NaturalLipopolysaccharide ReceptorsAntineoplastic AgentsBiomarkers, PharmacologicalEOMES protein, humanImmune Checkpoint InhibitorsInterferon-gammaLipopolysaccharide ReceptorsT-bet Transcription FactorT-Box Domain Proteinscancer immunotherapyCD4 T cellscheckpoint inhibitionCyTOFmelanomaNK cellsT cell exhaustion

Identifiers

PMID32210968
PMCPMC7076153
OpenAlexW3011956009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.